C

Cara Therapeutics
D

CARA

5.05000
USD
-0.02
(-0.39%)
مغلق
حجم التداول
50
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
23,084,706
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACB
    0.02000
    (0.34%)
    5.87000 USD
    C
    CGC
    0.01500
    (0.94%)
    1.61500 USD
    C
    CRBP
    -0.09000
    (-1.09%)
    8.20000 USD
    C
    CRON
    0.02500
    (1.29%)
    1.97000 USD
    T
    TLRY
    0.06110
    (7.03%)
    0.93000 USD
    المزيد
الأخبار
المقالات

العنوان: Cara Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.